Skip to main content

Table 1 Overview of ongoing angiotensin II antagonist trials in chronic heart failure (CHF) and post-myocardial infarction (post-MI) patients

From: ELITE II and Val-HeFT are different trials: together what do they tell us?

Study

Patients

Comparators

Size

Status

OPTIMAAL

Post-MI

Losartan vs captopril

n = 5477

Recruitment complete; end date 2002

VALIANT

Post-MI

Valsartan vs captopril vs combination

n = 14500

Recruitment complete; end date 2003

CHARM

CHF

Candesartan vs placebo

n = 2548

Recruitment complete; end date 2003

 

CHF (ACE intolerant)

Candesartan vs placebo

n = 2028

Recruitment complete

 

Diastolic dysfunction

Candesartan vs placebo

n = 3024

Recruitment complete

  1. ACE, angiotensin-converting enzyme.